Diabetes Drugs & Dementia Risk: Incretin Hope?
Nearly 60 million people worldwide are living with dementia, a number projected to triple by 2050. While research into disease-modifying treatments has largely stalled, a surprising new avenue is emerging: medications already in widespread use for type 2 diabetes. Specifically, drugs in the incretin class, known as GLP-1 receptor agonists, are showing remarkable potential not … Read more